Page 13 - Clinical Program News Today

TakedaTSE4502NYSETAK today announced full results from the pivotal Phase 3 ADVANCECIDP 1 clinical trial investigating HYQVIA Immune Globulin Infusion 10 Human with Recombinant Human Hyaluronidase as maintenance therapy in adult patients with chronic inflammatory demyelinating polyneuropathy CIDP.

Pivotal Phase 3 Findings with HYQVIA [Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase] Showed a Clinically Significant Reduction in Relapse Rate as well as a Delayed Time to... | June 20, 2023

Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Across all patients...

– PRGN-3005 was well-tolerated with no dose limiting toxicities, no CRS greater than Grade 2, and no neurotoxicity – – PRGN-3005 cells demonstrated expansion...

Late-breaking presentation will include new safety, kallikrein reduction and attack rate data across all dose cohorts in the Phase 1 portion of the studyIntellia to host investor webcast on Monday,... | May 31, 2023

Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress Halle (Saale) / Munich, Germany, May 16, 2023 - Vivoryon Therapeutics N.V. (Euronext

Vivoryon Therapeutics N.V. Reports Q1 2023 Financial Results and Highlights Operational Progress Halle (Saale) / Munich, Germany, May 16, 2023 - Vivoryon Therapeutics N.V. (Euronext

15.05.2023 - Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 (GLOBE NEWSWIRE) - Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the ...

Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data Expected in Mid-2023 WARREN, N.J., May 15, 2023 ...

/PRNewswire/ -- Horizon CME is pleased to announce Thanh Cao, CRNP, as the recipient of the 2023 Advanced Practice Provider Most Valuable Professional (APP...